Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study
Year: 1996
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Critical Care Medicine
Institution: Friedrich Schiller University Jena
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2034797939
